相关实验视频
Updated: Jun 22, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.8K
1型糖尿病的年轻人对糖化血红蛋白的非药理干预:贝叶斯网络元分析
Jacinto Muñoz-Pardeza1, José Francisco López-Gil2, Nidia Huerta-Uribe1
1Navarrabiomed, Hospital Universitario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.
Cardiovascular diabetology
|July 2, 2024
概括
多组分运动和营养补充剂显著改善了1型糖尿病的年轻人的血糖控制. 这些非药物干预措施减少了HbA1c和胰岛素需求,提供了潜在的辅助疗法.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 儿童糖尿病管理管理
背景情况:
- 关于在1型糖尿病中进行血糖控制的非药理干预措施的证据有限.
- 需要最佳策略来改善1型糖尿病年轻人的代谢健康.
研究的目的:
- 确定最佳的非药物干预措施,以改善1型糖尿病儿童和青少年的血糖控制 (HbA1c).
- 评估这些干预措施对每日胰岛素剂量要求的影响.
主要方法:
- 在PubMed,科学网,Scopus和SPORTDiscus的系统文献搜索,截至2023年7月1日.
- 74项随机临床试验 (RCT) 的网络元分析,涉及6815名参与者和20项干预措施.
- 主要结局:糖化血红蛋白 (HbA1c) 的变化;次要结局:每日胰岛素剂量的变化.
主要成果:
- 大多数干预措施在改善HbA1c方面比标准治疗更有效.
- 多组分运动 (有氧和力量训练) 显示出最大的HbA1c降低 (SMD: -0.63).
- 营养补充剂也显示出显著的HbA1c降低 (SMD: -0.49) 和减少胰岛素需求.
结论:
- 多组分运动和营养补充剂是治疗青少年1型糖尿病的有希望的非药物选择.
- 这些干预措施可以显著改善HbA1c水平并减少胰岛素需求.
- 需要进一步的研究,但这些方法可以作为有价值的辅助疗法.
相关概念视频
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180

